caa a22 4500 47583349X CHVBK 20180406123847.0 cr unu---uuuuu 170329e20000301xx s 000 0 eng 10.1023/A:1007874422754 doi (NATIONALLICENCE)springer-10.1023/A:1007874422754 Effect of Glycoprotein IIb/IIIa Inhibitors on the Individual Components of Composite Endpoints Used in Clinical Trials of Unstable Angina and Non-Q-Wave Myocardial Infarction [Elektronische Daten] [David Brown, Cathy Fann, Chee Chang] Inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor complex have recently been approved for the treatment of patients with unstable angina and non-Q-wave myocardial infarction (MI). We performed a meta-analysis to ascertain the effect of these agents on the individual endpoints of death, myocardial infarction, refractory ischemia, and major bleeding after 30 days of follow-up. Five randomized, placebo-controlled trials involving 17,255 patients were identified. The odds ratios for each of the endpoints in each trial were calculated and combined using a fixed-effects model. There was no significant reduction in death (OR, 0.87; 95% CI, 0.73-1.03; P = 0.1), myocardial infarction (OR, 0.91; 95% CI, 0.82-1.004; P = 0.06), or refractory ischemia (OR, 0.92; 95% CI, 0.78-1.1; P = 0.36) in patients treated with GP IIb/IIIa inhibitors. There was a significant increase in major bleeding following treatment with GP IIb/IIIa inhibitors (OR, 1.2; 95% CI, 1.06-1.4; P = 0.005). When used to treat unstable angina and non-Q-wave MI, this new class of agents appears to be associated with minimal clinical benefit and an increase in major bleeding complications. Kluwer Academic Publishers, 2000 platelet aggregation inhibitors nationallicence meta-analysis nationallicence unstable angina nationallicence myocardial infarction nationallicence Brown David Departments of Medicine (Cardiovascular Medicine), USA aut Fann Cathy Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA aut Chang Chee Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/3(2000-03-01), 253-258 0920-3206 14:3<253 2000 14 10557 https://doi.org/10.1023/A:1007874422754 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007874422754 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brown David Departments of Medicine (Cardiovascular Medicine), USA aut NATIONALLICENCE 700 1- Fann Cathy Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA aut NATIONALLICENCE 700 1- Chang Chee Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/3(2000-03-01), 253-258 0920-3206 14:3<253 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer